

		Reiml	bursement Policy	
Subject: Drugs and Injectable Limits				
Effective Date:	Committee Approv	al Obtained:	Section:	
01/01/20	11/25/20		Drugs	
*****The most current version of our reimbursement policies can be found on our provider				

\*\*\*\*\*The most current version of our reimbursement policies can be found on our provider website. If you are using a printed version of this policy, please verify the information by going to <a href="https://providers.healthybluela.com">https://providers.healthybluela.com</a>.\*\*\*\*

These policies serve as a guide to assist you in accurate claims submissions and to outline the basis for reimbursement if the service is covered by a Healthy Blue Dual Advantage (HMO D-SNP) member's plan. The determination that a service, procedure, item, etc. is covered under a member's benefit plan is not a determination that you will be reimbursed. Services must meet authorization and medical necessity guidelines appropriate to the procedure and diagnosis as well as to the member's state of residence. You must follow proper billing and submission guidelines. You are required to use industry standard, compliant codes on all claim submissions. Services should be billed with CPT® codes, HCPCS codes and/or revenue codes. The codes denote the services and/or procedures performed. The billed code(s) are required to be fully supported in the medical record and/or office notes. Unless otherwise noted within the policy, our policies apply to participating providers and facilities; a noncontracting provider who accepts Medicare assignment will be reimbursed for services according to the original Medicare reimbursement rates.

If appropriate coding/billing guidelines or current reimbursement policies are not followed, Healthy Blue Dual Advantage may:

- Reject or deny the claim.
- Recover and/or recoup claim payment.

Healthy Blue Dual Advantage reimbursement policies are developed based on nationally accepted industry standards and coding principles. These policies may be superseded by mandates in provider, state, federal, or CMS contracts and/or requirements. System logic or set up may prevent the loading of policies into the claims platforms in the same manner as described; however, Healthy Blue Dual Advantage strives to minimize these variations.

Healthy Blue Dual Advantage reserves the right to review and revise its policies periodically when necessary. When there is an update, we will publish the most current policy to the website.

Policy	Healthy Blue Dual Advantage will apply Clinical Unit Limits (CUL) to drugs that may be based on manufacturer's guidelines, U.S. Food and Drug Administration (FDA) approval, and/or code description unless provider, federal or CMS contracts and/or requirements indicate otherwise.
	Drug claims must be submitted as required with applicable HCPCS or CPT procedure code(s), National Drug Codes, appropriate qualifier,

	unit of measure, and number of units. Units should be reported in the multiples included in the code descriptor used for the applicable HCPCS codes.  Reimbursement will be considered up to the CUL or state-mandated limits or CMS Medically Unlikely Edit (MUE) limits allowed for the prescribed/administered drug. When there is no MUE assigned by CMS, identified codes will have a CUL assigned or calculated based on the prescribing information, the FDA and established reference compendia.		
	Claims that exceed the CUL will be reviewed for documentation to support the additional units. If the documentation does not support the additional units billed, the additional units will be denied.		
History	<ul> <li>Biennial review approved 11/25/20: Added first sentence and clarified policy language</li> <li>Initial approval and effective date 01/01/20</li> </ul>		
References and Research Materials	<ul> <li>This policy has been developed through consideration of the following:</li> <li>CMS</li> <li>State contract</li> <li>Healthy Blue contract(s)</li> </ul>		
Definitions	<ul> <li>The appropriateness of the specific treatment for which a drug is being prescribed is recognized and supported in one of the following established reference compendia:         <ul> <li>American Hospital Formulary Service — Drug Information</li> <li>National Comprehensive Cancer Network Drugs and Biologics Compendium</li> <li>Thomson Micromedex DrugDex®</li> <li>Elsevier Gold Standard Clinical Pharmacology</li> </ul> </li> <li>General Reimbursement Policy Definitions</li> </ul>		
Related Policies	<ul> <li>Claims Submission — Required Information for Professional Providers</li> <li>Unlisted, Unspecified and Miscellaneous Codes</li> </ul>		
Related Materials	• None		